PTPRT and melanoma: Based on the results from TCGA melanoma and NSCLC cohorts, patients with PTPRT mutations did not exhibit the clinical benefits of simply chemotherapy (Figure S9A,B), but had the favorable treatment prognosis in patients treated with immune checkpoint‐based agents, suggesting the specific predictive roles of PTPRT mutations in the immunotherapy settings.